February 14, 2021
Yashu Dhamija, MD, a first-year fellow in the University of Cincinnati Department of Immunology, Allergy and Rheumatology, speaks with Yahoo Life about his latest research. The immunologist describe a case study of a patient who developed contact dermatitis after wearing facemasks during the COVID-19 pandemic.
March 10, 2021
A University of Cincinnati rheumatologist weighs in as the German Society for Rheumatology updates its guidelines to reflect the impact of the COVID-19 pandemic.
July 4, 2020
UC digestive diseases expert Kenneth Sherman, MD, PhD, discusses study showing COVID-19 patients in China shown mildly elevated liver enzyme levels.
September 14, 2020
Carl Fichtenbaum, MD, was interviewed by CNN for a story they published about a delay in the Astra-Zeneca COVID-19 vaccine trial.
April 14, 2022
A report published recently in JAMA Open Network finds there's a strong likelihood that the antidepressant fluvoxamine (Luvox) may moderately lower rates of hospitalization due to COVID-19 in unvaccinated patients. However, outside experts cited by Medscape differ over whether the evidence from just three studies is strong enough to warrant adding the drug to the COVID-19 armamentarium. One of those experts sources is Carl Fichtenbaum, MD, of the Division of Infectious Diseases at the UC College of Medicine.
September 29, 2021
Several companies, including Pfizer are developing a pill to fight COVID-19 symptoms. Carl Fichtenbaum, MD, of the Division of Infectious Diseases at the UC College of Medicine was interviewed by WKRC-TV, Local12 for a story about the antiviral medications and explained how they work.
October 8, 2021
Carl Fichtenbaum, MD, and Jennifer Forrester, MD, both of the Division of Infectious Diseases at the UC College of Medicine were interviewed for a story posted on Cincinnati.com on what experts would advise parents to do in regards to handing out candy on Halloween.
October 11, 2021
Carl Fichtenbaum, MD, of the Division of Infectious Diseases at the UC College of Medicine was one of the sources cited in an article in Medscape on pharmaceutical company Merck developing a new pill for COVID-19. Fichtenbaum said it wasn't a 'home run' but it was encouraging.